# Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)

> **NCT06090656** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 88 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Bevacizumab combined with Sintilimab
- **PROCEDURE:** Transcatheter arterial chemoembolization

## Key facts

- **NCT ID:** NCT06090656
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-02
- **Primary completion:** 2025-07-25
- **Final completion:** 2025-07-25
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06090656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06090656, "Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06090656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*